FactaeThe Factual News

Nicox and partner submit registration dossier for ophthalmic treatment in China

Nicox announces the submission of an NDA for its NCX 470 treatment in China.

Published 2h1 sourceNotable
Lire en français
≈ 19s

The fact

The dossier was filed by its partner Ocumension with Chinese authorities.

This step marks a major milestone for the product's commercial development.

Click the link to read an article on the topic:
Explore this topic
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.
ChineWorld map →
Follow topic →
Auto-synthesis from 1 media source · identified on August 10, 2026
← Back to home
Discover

Read more

All marches →
marches

Nicox submits marketing authorization application for NCX 470

5sem · 1 sourcemarches

Nicox reveals the future commercial designation of its NCX470 treatment

1sem · 1 sourcemarches

Nicox announces positive regulatory feedback in June

7sem · 1 sourcemarches15 %

Nicox faces financial difficulties after failure of ophthalmic treatment

6sem · 1 sourcemarches

Nicox secures backing from shareholder and strategic financial partner

6sem · 1 source